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Abstract
Aims/hypothesis Insulinoma-associated protein 2 (IA-2) is a
major target of autoimmunity in type 1 diabetes. When first
detected, IA-2-autoantibodies commonly bind epitopes in the
juxtamembrane (JM) domain of IA-2 and antibody responses
subsequently spread to the tyrosine phosphatase domain.
Definition of structures of epitopes in the JM domain, and
genetic requirements for autoimmunity to these epitopes, is
important for our understanding of initiation and progression
of autoimmunity. The aims of this study were to investigate
the contribution of individual amino acids in the IA-2 JM
domain to antibody binding to these epitopes and the role of
HLA genotypes in determining epitope specificity.
Methods Regions of the JM domain recognised by autoanti-
bodies were identified by peptide competition and inhibitory
effects of alanine substitutions of residues within the JM re-
gion. Antibody binding was determined by radioligand bind-
ing assays using sera from patients genotyped for HLA-DRB1
and -DQB1 alleles.
Results Patients were categorised into two distinct groups of
JM antibody reactivity according to peptide inhibition.
Inhibition by substitutions of individual amino acids within
the JM domain differed between patients, indicating heteroge-
neity in epitope recognition. Cluster analysis defined six
groups of residues having similar inhibitory effects on anti-
body binding, with three clusters showing differences in pa-
tients affected or unaffected by peptide. One cluster demon-
strated significant differences in antibody binding between
HLA-DRB1*04 and HLA-DRB1*07 patients and within
DRB1*04 individuals; antibody recognition of a second clus-
ter depended on expression of HLA-DQB1*0302.
Conclusions/interpretation The results identify amino acids
contributing to distinct epitopes on IA-2, with both HLA-DR
and HLA-DQ alleles influencing epitope specificity.
Keywords Autoantibodies . Epitopes .HLA-DQ .HLA-DR .
IA-2
Abbreviations
cDNA Complementary DNA
GADA Antibodies to glutamate decarboxylase
IA-2ic Intracytoplasmic domain of insulinoma-associated
protein 2
JM Juxtamembrane
PTP Protein tyrosine phosphatase
ZnT8A Antibodies to zinc transporter-8
Introduction
The strong association of HLA-DRB1*03, -DRB1*04 and
linked DQ alleles with the development of type 1 diabetes is
long established but the molecular mechanisms underlying
HLA-mediated susceptibility are still obscure. It is widely
accepted that HLA gene products mediate their effects via
the presentation of peptides derived from islet autoantigens
[1], and associations between expression of HLA alleles and
the presence of antibodies to the autoantigens glutamate
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decarboxylase (HLA-DRB1*03) [2], insulin (HLA-DRB1*04)
[3] and insulinoma-associated protein 2 (IA-2;HLA-DRB1*04,
HLA-DRB1*07 and HLA-DRB1*09) [4, 5] support roles for
HLA in regulating autoimmune responses to specific islet
proteins. For the IA-2 autoantigen, relationships between
HLA-DRB1*04 expression, the detection of T cell responses
to specific IA-2 peptides and the presence of autoantibodies to
specific regions of the antigen provide evidence of close links
of HLA alleles with both Tcell and B cell responses to a major
autoantigen in type 1 diabetes [6]. B cell responses to IA-2 in
the period before diabetes onset are progressive, with antibod-
ies in the early phase of disease frequently recognising epi-
topes within the juxtamembrane (JM) domain of the protein,
later spreading to epitopes in the protein tyrosine phosphatase
(PTP) domain and to the closely related IA-2beta [7]. This
diversification of the autoimmune response may be critical
for disease progression [7]. Within the JM domain of IA-2
there are at least two distinct epitope regions, and B cell re-
sponses to these show different associations with HLA alleles
[8]. The aim of this study was to fine-map epitopes for type 1
diabetes-associated autoantibodies within the JM domain of
IA-2 by alanine scanning mutagenesis and to further explore
HLA associations with antibody recognition of the epitope
regions identified.
Methods
Participants Blood samples were obtained from 140 type 1
diabetic patients recruited within 6 months of diagnosis of
disease from clinics in West Yorkshire and King’s College
Hospital, London, UK with informed consent and approval
from the Yorkshire and the Humber – Bradford Leeds and
the King’s College Hospital Research Ethics Committees for
studies on the specificity of B cell and T cell responses in
disease. Ethical approval for the study in Yorkshire restricted
recruitment to patients ≥12 years of age, so there was an
under-representation of young children. The mean age of pa-
tients was 18.8 years (range 8–36 years) and 94 (67%) were
male. Blood samples were used for analysis of serum autoan-
tibodies (see below) and for genotyping of HLA-DRB1 and
-DQB1 loci by PCR amplification of genomic DNA using
sequence-specific primers [9]. The autoantibody frequency
and HLA genotypes expressed by the patients studied are
shown in Table 1.
Antibody analysis Antibodies to glutamate decarboxylase
(GADA), zinc transporter-8 (ZnT8A), and the intracytoplasmic
(IA-2ic, residues 606-979) and PTP (694-979) domains of IA-2
were analysed by radioligand binding assay as previously de-
scribed [10–12]. The sensitivity and specificity of the IA-2
antibody test in the 2012 Immunology of Diabetes Society
Autoantibody workshop was 62% and 100%, respectively.
Antibodies to the IA-2 JM domain (residues 606–700) were
analysed using complementary DNA (cDNA) representing a
chimeric construct in which residues 701–910 of the IA-2ic
domain were replaced by residues 5–216 of human PTP1B,
thereby deleting PTP domain epitopes. The cDNA for the
IA-2 JM chimera was transcribed and translated in vitro in
the presence of 35S-methionine (PerkinElmer, Coventry, UK)
using the TNT Quick coupled transcription and translation sys-
tem (Promega, Southampton, UK). Radiolabelled protein
representing 20,000 cpm was incubated with test sera for
16 h at 4°C and a polyclonal rabbit antibody to IA-2 with
predominant reactivity to the JM domain was included as a
positive control. JM antibody units for each sample were cal-
culated as a percentage of radioactivity immunoprecipitated by
antibodies in the sample relative to that of the positive control.
For peptide blocking studies, 5 μg of synthetic IA-2 peptides
representing amino acids 601–620, 611–630 and 621–640 of
IA-2 were added during the incubation. Immune complexes
were captured on protein A Sepharose (Sigma, Poole, UK)
and, after washing, the quantity of radiolabelled antigen bound
was determined by scintillation counting. Peptides representing
amino acids outside the 601–640 region did not block serum
autoantibody binding to the IA-2 JM domain construct.
To evaluate the contribution of single amino acids within
the JM domain to autoantibody binding, mutant IA-2 JM chi-
mera constructs incorporating alanine substitutions at residues
described in the text were generated using the QuikChange
site-directed mutagenesis kit (Agilent Technologies,
Stockport, UK) according to the manufacturer’s instructions.
Successful incorporation of mutations was confirmed by se-
quencing (Source Bioscience, Nottingham, UK). Mutant
Table 1 Immune and
HLA characteristics of
the patient population
Variable n (%)
Total number 140
GADA 114 (81%)
ZnT8A 82 (59%)
IA-2A 96 (69%)
IA-2-PTPA 78 (56%)
IA-2-JMA 51 (36%)
HLA-DRB1*03/DRB1*04 37 (26%)
HLA-DRB1*04/DRB1*04 12 (9%)
HLA-DRB1*04/X 35 (25%)
HLA-DRB1*03/DRB1*03 17 (12%)
HLA-DRB1*03/X 20 (14%)
HLA-X/X 19 (14%)
Numbers (n) and frequency (%) for posi-
tivity for islet autoantibodies and HLA ge-
notypes are shown
IA-2A, antibodies to IA-2ic; IA-2-JMA,
antibodies to IA-2 JM; IA-2-PTPA, anti-
bodies to IA-2 PTP; X, non-HLA-
DRB1*03 or DRB1*04
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constructs were transcribed and translated in vitro in the pres-
ence of 35S methionine and used together with wild-type con-
structs in radioligand binding assays as described above. The
effect of individual amino acid substitutions on binding to
autoantibodies in patients’ sera was calculated relative to that
of the wild-type construct as per cent inhibition.
Statistical analysis Similarities in inhibitory effects of indi-
vidual amino acid substitutions on binding of antibodies in
type 1 diabetic patients to mutated IA-2 JM constructs were
analysed by hierarchical cluster analysis by use of the furthest
neighbour method using the Statistics Package for Social
Sciences version 22 (SPSS; IBM, Portsmouth, UK). The sig-
nificance of differences in inhibitory effects of individual or
clusters of amino acid substitutions were analysed by two-way
ANOVAwith Sidak’s correction for multiple comparisons, or
by Student’s t-test, as appropriate. ANOVA and t-tests were
performed using Prism version 6 (GraphPad Software,
La Jolla, CA, USA). Data are presented as means ± SEM.
Results
Characterisation of IA-2 JM domain autoantibodies in
type 1 diabetes The use of chimeric IA-2 constructs and com-
petition studies using synthetic peptides has previously iden-
tified two distinct epitopes within the IA-2 JM domain
contained within IA-2 regions 611–620 (JM1) and 621–630
(JM2) [8]. Substitutions of amino acids within the 619–631
region have revealed further heterogeneity in autoantibody
recognition of the JM domain [13]. To define autoantibody
epitopes within this region, sera from patients positive for
antibodies to the IA-2 JM chimera were initially used in com-
petition studies with synthetic 20-mer peptides. Alanine scan-
ningmutagenesis was subsequently performed over the region
608–639 of the IA-2 JM domain.
Of the 51 patients positive for antibodies to the IA-2 JM
chimera in the initial screen, there was sufficient serum from
49 for detailed characterisation of antibody recognition of epi-
topes within the JM domain. These samples could be segre-
gated into two groups on the basis of inhibition by a synthetic
20-mer peptide representing the 601–620 region of IA-2.
Thus, 25 patients demonstrated ≤10% inhibition of antibody
binding to the IA-2 JM construct by the peptide, with the
remainder being inhibited by 30–95% (Fig. 1a). Samples
inhibited by the 601–620 peptide had JM antibody levels of
<80 units (Fig. 1b). This resistance to peptide inhibition was
retained after serial dilution of those samples with high JM
antibody levels to submaximal levels of antigen binding. The
average inhibition by peptide of binding of antibodies in the
eight sera with the highest JM antibody levels at neat, 1:2 and
1:4 dilutions were 1.26%, 4.91% and 0.26%, respectively.
Antibody binding for almost all samples was inhibited by
the 611–630 and 621–640 peptides (Fig. 1a), which suggests
a crucial role of the 621–640 region of IA-2 in binding of all
JM autoantibodies. Inhibition by 611–630 and 621–640 pep-
tides was independent of JM antibody levels (Fig. 1c, d).
To identify specific amino acids implicated in serum auto-
antibody recognition of JM domain epitopes, alanine substitu-
tions of individual amino acids represented by the 608–639
region of IA-2 were made in the IA-2 JM chimeric construct.
The influence of each substitution on binding of autoantibodies
Fig. 1 Scatter plots (a) showing
inhibitory effects of synthetic
20-mer peptides representing
amino acids 601–620, 611–630
and 621–640 on serum antibody
binding to an IA-2 JM domain
construct. Inhibition of individual
patients’ antibodies is expressed
as per cent inhibition of binding in
absence of peptide. The
relationships of inhibition by
peptides 601–620 (b), 611–630
(c) and 621–640 (d) to levels of
antibodies to the IA-2 JM domain
construct are also shown
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in sera from the 49 patients positive for antibodies to the IA-2
JM chimera was then evaluated. Clear differences were ob-
served in the inhibitory effects of individual amino acid substi-
tutions on antibody binding between samples that were
inhibited or unaffected by the 601–620 peptide in the compe-
tition studies (Fig. 2a). Inhibition by individual alanine substi-
tutions was largely independent of JM antibody levels in indi-
vidual sera, with the exception of two residues in cluster 3,
residues 611 and 612, where the highest inhibition was seen
in low titre sera. Samples in which antibody binding was
inhibited by the 601–620 peptide showed significantly higher
mean inhibition by alanine substitutions of amino acids 612,
616, 618 and 619, whereas those unaffected by the peptide
demonstrated greater inhibition by substitutions of amino acids
609, 621 and 622. Substitutions of amino acids 615, 631, 633,
634, 635 and 636 influenced antibody binding, but affected
samples irrespective of inhibition by the 601–620 peptide in
the competition study.
Similarities amongst individual amino acids in inhibitory
effects on serum antibody binding after alanine substitution
were investigated by hierarchical cluster analysis in order to
identify groups of residues that may contribute to common
antibody epitopes. The analysis identified six distinct clusters
grouped with distance ≤10 in the dendrogram from the anal-
ysis (Fig. 2b). Samples categorised according to inhibitory
effects of the 601–620 peptide showed different mean inhibi-
tion by substitutions of amino acids within each cluster.
Substitutions in amino acids grouped as cluster 3 (residues
611, 612, 618, 619, 623) preferentially affected samples
inhibited by the 601–620 peptide, whereas those in cluster 5
(621, 622) and cluster 6 (609, 625, 626, 627) showed strong
inhibitory effects in those unaffected by the peptide (Fig. 3a).
Substitutions of amino acids in cluster 4 (615, 616, 631, 633,
635, 636) affected most samples irrespective of peptide
601–620 inhibition, whereas those in cluster 1 (630 and 639)
and cluster 2 (608, 610, 624, 628, 629, 632, 638) rarely
affected antibody binding.
Influence ofHLA alleles on JMantibody bindingThemean
inhibition of serum antibody binding by substitution of amino
acids within each cluster shown in Fig. 2b was used to analyse
the effects of HLA-DR and HLA-DQ alleles on autoantibody
recognition of epitopes within the IA-2 JM domain. The major-
ity of the 49 patients positive for IA-2-JM antibodies in the
epitope analysis expressed either HLA-DRB1*04 (n=37) or
HLA-DRB1*07 (n=7). Patients expressing HLA-DRB1*07
had significantly higher mean inhibition by substitution of
cluster 3 amino acids (611, 612, 618, 619, 623) than those with
HLA-DRB1*04 (Fig. 3b). Within HLA-DRB1*04 patients, sig-
nificant differences in mean inhibition by residues 621 and 622
(cluster 5) were observed between those withHLA-DQB1*0302
and –DQB1*0301 alleles (Fig. 3c). Furthermore, patients
with HLA-DRB1*03/DRB1*04, -DRB1*01/DRB1*04 or
–DRB1*04/DRB1*13 had significantly lower mean inhibi-
tion by substitutions of cluster 3 residues (8.4±4.7%, n=26)
than those with other HLA genotypes (30.9±5.4%, n=23;
p<0.005). The results demonstrate influences of both
HLA-DR and DQ genes on autoimmune recognition of the
IA-2 JM domain.
Discussion
The first appearance of IA-2 autoimmunity in type 1 diabetes
is often associatedwith the early detection of autoantibodies to
Fig. 2 (a) Influence of substitutions of individual amino acids within the
608–639 region of IA-2 expressed in the IA-2 JM domain construct on
binding of antibodies in sera from 49 JM antibody-positive patients
grouped according to inhibitory effects (white bars, not inhibited; black
bars, inhibited) of peptide 601–620. The significance of differences of
effects of individual amino acid substitutions between groups affected or
not affected by the 601–620 peptide is shown (*p<0.05, **p<0.01,
***p<0.001). (b) Dendrogram illustrating results of cluster analysis of
data from experiments evaluating similarities in inhibitory effects of in-
dividual amino acid substitutions. Residues with similar inhibitory effects
are grouped into clusters defined by distance in the dendrogram being ≤10
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the JM domain of the molecule. The association of the JM
antibody response with HLA-DRB1*04, both in the period
before and at the time of diabetes onset, in this study and other
studies [6, 8] implicates immune responses to determinants
within the JM domain as a potential contributor to diabetes
susceptibility conferred by this allele. There is evidence of
heterogeneity in autoantibody epitopes within the JM domain
[13] and autoimmune responses to individual JM domain epi-
topes may have different associations with HLA genotypes
[8]. In order to better understand the potential role of autoim-
munity to the IA-2 JM domain in HLA-mediated disease sus-
ceptibility, we have undertaken a detailed analysis of the ef-
fects of individual amino acids within the IA-2 JM domain on
autoantibody binding to identify clusters of amino acids with
similar inhibitory effects of alanine substitution, implicit of
common epitope regions. Antibody recognition of these epi-
tope clusters is associated with different HLA-DR and DQ
genotypes, consistent with a role for the products of these loci
in the regulation of autoimmunity to the IA-2 JM region.
In agreement with previous observations of at least two
distinct patterns of autoantibody binding to the IA-2 JM do-
main designated JM1 and JM2 [8], patients with type 1 dia-
betes in this study could be allocated to two groups according
to inhibitory effects on antibody binding of a synthetic peptide
representing the 601–620 region of the protein (Fig. 1a).
However, alanine scanning mutagenesis revealed further het-
erogeneity between patients in amino acids affecting binding
of antibodies, suggesting that the precise structure of epitopes
in the JM1 and JM2 regions differed between patients. Groups
of amino acids showing similarities in inhibitory effects of
alanine substitution could be identified by cluster analysis,
and these may represent common epitopes on the molecule
recognised by subgroups of patients. The amino acid clusters
could be categorised according to their general influence on
antibody binding: (1) those residues where alanine substitu-
tion had minimal effects on antibody binding with most sera
(clusters 1, 2); (2) residues where substitution affected
antibody binding primarily in patients whose IA-2 JM anti-
bodies were inhibited by the 601–620 peptide (cluster 3); (3)
residues that contributed to antibody binding in patients with
IA-2 JM antibodies unaffected by the 601–620 peptide (clus-
ters 5, 6); and (4) residues where alanine substitution inhibited
binding of antibodies in most sera, irrespective of effects of
the 601–620 peptide (cluster 4). Lampasona et al [13] have
previously analysed the effects of amino acid substitutions in
the 619–631 region of IA-2 and we observed similar findings.
Hence, inhibitory effects of alanine substitution of residue 619
(within cluster 3 in our study) defined a ‘JM1’ epitope in the
Lampasona study and those of residues 621 and 622 (cluster
5) and 625, 626 and 627 (cluster 6) were found in all ‘JM2’
designated sera illustrated in the paper.
We have now extended the analysis of effects of amino acid
substitutions across the entire JM epitope region. Our results
demonstrate that mutations of amino acids that are widely
separated in the linear IA-2 sequence affect binding of anti-
bodies in individual patient sera and are contained within
clusters of amino acids with similar inhibitory effects on anti-
body binding. It has previously been suggested that antibodies
to the JM domain bind linear epitopes, on the basis that these
can be represented by short sequences of JM amino acids
contained within, for example, synthetic peptides [8]. Our
new data suggest that, like other defined epitopes for antibod-
ies in type 1 diabetes, protein conformation is also important
for optimal binding of antibodies to the IA-2 JM domain, with
noncontiguous amino acids contributing to the antibody epi-
topes. In particular, cluster analysis identified similar inhibito-
ry effects of residues 609, 625, 626 and 627 (cluster 6) on JM
antibody binding, with residue 609 being relatively far in the
linear sequence of the JM domain from other contributing
residues. This finding suggests either that alanine substitution
of the lysine at residue 609 disturbs the conformation of the
625–627 region, for example by disrupting ionic interactions,
or that the JM region is folded such that residue 609 is brought
in close proximity to the 625–627 region and participates
Fig. 3 Mean per cent inhibition by alanine substitutions of residues with-
in clusters 1–6 shown in Fig. 2b on the binding of antibodies in sera from
49 type 1 diabetic patients to the IA-2 JM construct. Patients were
grouped according to (a) effects of peptide 601–620 on JM antibody
binding (white bars, not inhibited; black bars, inhibited); (b) HLA-DR
alleles (white bars, HLA-DRB1*04; black bars, HLA-DRB1*07; grey
bars, other HLA alleles); or (c) HLA-DQ alleles within the HLA-
DRB1*04 patients (white bars, HLA-DRB1*04-DQB1*0301; black bars,
HLA-DRB1*04-DQB1*0302). The significance of differences of the
mean inhibition by amino acid substitutions within each cluster between
patients grouped according to peptide 601–620 inhibition (a) or HLA
alleles expressed (b, c) is shown (*p<0.05, **p<0.01, ****p<0.0001)
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directly in antibody binding. Mouse monoclonal antibodies to
the IA-2 JM domain having similar binding characteristics to
those seen in human type 1 diabetes [14, 15], also displayed
sensitivity to amino acid substitutions within noncontiguous
regions of the JM domain [16]. Thus, four different mouse
monoclonal antibodies to the IA-2 JM domain were all
inhibited by alanine substitutions in the cluster 4 amino acids
615, 635 and 636, with each antibody being also affected by
different amino acid substitutions elsewhere in the JM do-
main, similar to the observations with the patient sera.
Together these results identify two distinct regions located at
either end of the JM antibody-binding region each containing
cluster 4 residues, one represented by amino acids 615 and
616 and the other by residues 631, 633, 634, 635 and 636, that
have general importance for autoantibody binding, with the
characteristic epitope for the antibody being defined by more
specific inhibitory effects of substitutions of amino acids with-
in clusters 3, 5 or 6. The epitope represented by amino acids in
cluster 3 is dominant in sera inhibited by the 601–620 peptide
(defined as JM1 epitope in [8]) and patients with antibodies to
this epitope tend to have lower JM antibody levels, as seen for
antibodies inhibited by the 601–620 peptide (Fig. 1b) and
those affected by alanine substitution of the cluster 3 residues
611 and 612.
Our data also suggest that autoantibody reactivity to specific
epitopes represented by amino acids within clusters 3 and 5may
be influenced by HLA (Fig. 3b, c). It has been demonstrated
previously that autoantibody responses to the IA-2 JM domain
are associated with expression of HLA-DRB1*04 [8], with au-
toantibody frequencies being similar in DRB1*04-DQB1*0301
and DRB1*04-DQB1*0302 individuals, suggesting a primary
association with the DR, rather than DQ, locus [6]. However,
dissection of the JM autoantibody response to individual
epitopes reveals a more complex influence of the HLA
region on the specificity of autoimmunity to the JM domain,
with involvement of both HLA-DR and HLA-DQ alleles.
Substitution of amino acids within cluster 3 produced signif-
icantly higher inhibition of antibody binding in patients
expressing HLA-DRB1*07. HLA-DRB1*07 has different ef-
fects on disease susceptibility depending on the HLA-DQA
genotypes expressed [17]. A positive association of
HLA-DRB1*07 with IA-2 autoantibodies has previously
been reported and the authors suggested that this association
may be secondary to effects of HLA-DQA1 alleles [5]. In that
study, JM antibodies were negatively associated with
HLA-DRB1*07, although the analysis used a chimeric con-
struct missing region 633–636 that, according to the results of
our study, may be required for optimal JM antibody binding.
The two studies are, nevertheless, consistent with an influence of
HLA-DRB1*07 or linked HLA-DQ gene products on the IA-2
autoimmune response. Patients with HLA-DRB1*03/DRB1*04,
DRB1*01/DRB1*04 or DRB1*04/DRB1*13 had significantly
lower inhibition by cluster 3 substitutions than other HLA
genotypes. This observation is consistent with the findings of
Bearzatto et al [8], who found that antibodies to the JM2 epitope
in the absence of those to JM1 (cluster 3 in our study) were
found in relatives of individuals with type 1 diabetes with
HLA-DRB1*03/DRB1*04, DRB1*01/DRB1*04 or DRB1*04/
DRB1*13 genotypes. Furthermore, inhibitory effects of cluster
5 substitutions on JM antibody binding were associated
with HLA-DQB1*0302 expression within HLA-DRB1*04
patients, suggesting that this major type 1 diabetes suscep-
tibility allele may influence the specificity of the IA-2 autoim-
mune response, in particular to the JM region that may dom-
inate around the time of first appearance of IA-2 autoimmu-
nity. This association is almost certainly secondary to a prima-
ry association of DQ8-restricted T cell responses to as yet
undefined T cell determinants. Candidates may include pep-
tides within the region 601–633 that have been shown to spe-
cifically stimulate T cell responses in HLA-DQB1*0302
transgenic mice [18].
The results of our study define epitopes for autoantibodies in
a region of an autoantigen known to be important in the early
phases of autoimmunity in type 1 diabetes and demonstrate an
influence of bothHLA-DR and -DQ alleles on the specificity of
B cell responses to the IA-2 JM region. Autoantibody re-
sponses to the JM domain are primarily associated with the
expression of HLA-DRB1*04, but antibodies in patients ex-
pressingHLA-DRB1*07 recognise a specific epitope represent-
ed by amino acids 611, 612, 618, 619 and 623. Furthermore, in
HLA-DRB1*04 patients, antibody recognition of epitopes de-
fined by residues 621 and 622 is impaired ifHLA-DQB1*0301,
rather than HLA-DQB1*0302, is expressed. The data illustrate
the importance of dissecting the autoantibody response to indi-
vidual epitopes on autoantigens to reveal responses influenced
by HLA haplotypes expressed by the diabetic patient.
Identification of T cell determinants with appropriate HLA
restriction that are associated with responses to JM epitopes
defined in this study will help to understand the molecular basis
of HLA-mediated susceptibility to type 1 diabetes.
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